Document Detail

Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers.
MedLine Citation:
PMID:  3881908     Owner:  NLM     Status:  MEDLINE    
Raynaud's phenomenon may be associated with severe pain, functional disability and digital infarction, particularly in patients with underlying vascular disease. The pathophysiologic features of Raynaud's phenomenon are complex although vasospasm contributes to the production of digital ischemia in most cases. Calcium-channel blockers have been shown to produce arteriolar vasodilation and an increase in peripheral blood flow. They have been used to treat patients with Raynaud's phenomenon in several prospective, randomized, double-blind, placebo-controlled trials. Low doses of verapamil were ineffective but both diltiazem and nifedipine produced subjective improvement in 60 to 90% of cases. Objective measures of digital blood flow were not improved. Patients without underlying vascular disease responded more readily to therapy than patients with scleroderma. Adverse effects were uncommon and seldom necessitated discontinuation of therapy. These data suggest that nifedipine and diltiazem provide effective short-term improvement in symptoms for most patients with Raynaud's phenomenon.
C R Smith; R J Rodeheffer
Related Documents :
17331868 - Syme amputation for limb salvage: early experience with 26 cases.
22006688 - Subclinical autonomic dysfunction in spinobulbar muscular atrophy (kennedy disease).
11128888 - Short-term effects of dynamic lycra splints on upper limb in hemiplegic patients.
22494508 - Extranodal non-hodgkin lymphomas of the oral cavity and maxillofacial region: a clinica...
373438 - Identification of the high-risk asthmatic patient. experience with 39 patients undergoi...
25249218 - Macular telangiectasia type 2 (mactel) in a 34-year-old patient.
Publication Detail:
Type:  Clinical Trial; Journal Article; Review    
Journal Detail:
Title:  The American journal of cardiology     Volume:  55     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1985 Jan 
Date Detail:
Created Date:  1985-02-26     Completed Date:  1985-02-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  154B-157B     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Calcium Channel Blockers / administration & dosage,  therapeutic use*
Clinical Trials as Topic
Diltiazem / therapeutic use
Double-Blind Method
Nifedipine / therapeutic use
Prospective Studies
Random Allocation
Raynaud Disease / drug therapy,  physiopathology*
Verapamil / therapeutic use
Reg. No./Substance:
0/Calcium Channel Blockers; 21829-25-4/Nifedipine; 42399-41-7/Diltiazem; 52-53-9/Verapamil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of calcium antagonists in cerebral arterial spasm.
Next Document:  Modification of experimental atherosclerosis by calcium-channel blockers.